|
|
||||||||
Journal of Lipid Research, Vol 37, 2383-2393, Copyright © 1996 by Lipid Research, Inc.
KG Parhofer, PH Barrett, T Demant, WO Richter and P Schwandt
Apheresis is a treatment option for patients with severe
hypercholesterolemia and coronary artery disease. It is, however, unknown
whether such therapy changes kinetic parameters of lipoprotein metabolism,
such as apolipoprotein B (apoB) secretion rates, conversion rates, and
fractional catabolic rates (FCR). We studied the long-term effect of
regular apheresis therapy on metabolic parameters of apoB in five patients
with heterozygous familial hypercholesterolemia (FH) using endogenous
labeling with D3-leucine, mass spectrometry, and multicompartmental
modeling. Patients were studied prior to (study 1) and after 3-6 months of
weekly apheresis therapy (study 2). LDL-apoB concentration was 183 +/- 16
mg d-1 prior to apheresis therapy (study 1), 135 %/- 7 mg. dl-1 at the
beginning of study 2, and 163 +/- 10 mg . dl-1 at the end of study 2.
VLDL-apoB and IDL-apoB were not different between the two studies and did
not change during study 2. Separate modeling of the two studies revealed
very similar parameters in each patient. In a second step simultaneous
modeling of both studies was performed taking the changing pool size as a
non-steady-state condition into account. ApoB tracer data of both kinetic
studies and the change in pool size could be described with one set of
kinetic parameters (VLDL-apoB FCR 4.32 +/- 1.06 d-1, LDL-apoB FCR 0.17 +/-
0.05 d-1, apoB secretion rate 11.9 +/- 3.7 mg . kg-1 . d-1). These
parameters are well within the range of those previously published for FH
heterozygotes in steady state. We conclude that regular apheresis therapy
did not alter kinetic parameters of apoB metabolism in these patients with
heterozygous FH in the long term and that the decreased rate of delivery of
neutral lipids or apoB to the liver does not regulate plasma apoB
metabolism.
ARTICLES
Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia
Department of Internal Medicine II, Klinikum Grosshadern, Ludwig- Maximilians Universitat Munchen, Munich, Germany.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. D. Kolovou, G. V.Z. Dedoussis, K. K. Anagnostopoulou, G. Ch. Hatzigeorgiou, K. D. Salpea, D. M. Choumerianou, S. Rammos, D. P. Mikhailidis, and D. V. Cokkinos Management of a Patient With a Null Low-Density Lipoprotein Receptor Mutation: A Case Report Angiology, January 1, 2007; 57(6): 729 - 732. [Abstract] [PDF] |
||||
![]() |
K. G. Parhofer and P. H. R. Barrett Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies J. Lipid Res., August 1, 2006; 47(8): 1620 - 1630. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Maugeais, K. Ouguerram, R. Frénais, P. Maugère, B. Charbonnel, T. Magot, and M. Krempf Effect of Low-Density Lipoprotein Apheresis on Kinetics of Apolipoprotein B in Heterozygous Familial Hypercholesterolemia J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1679 - 1686. [Abstract] [Full Text] |
||||
![]() |
K. G. Parhofer, P. H. R. Barrett, T. Demant, and P. Schwandt Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B J. Lipid Res., October 1, 2000; 41(10): 1596 - 1603. [Abstract] [Full Text] |
||||
![]() |
F. Pont, L. Duvillard, B. Verges, and P. Gambert Development of Compartmental Models in Stable-Isotope Experiments : Application to Lipid Metabolism Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 853 - 860. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |